(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 November 2010 (18.11.2010)

PCT

(10) International Publication Number
WO 2010/130423 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/445* (2006.01)
A61K 31/437 (2006.01) *A61P 25/00* (2006.01)
A61K 31/444 (2006.01)

(21) International Application Number:
PCT/EP2010/002909

(22) International Filing Date:
11 May 2010 (11.05.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09160064.3 12 May 2009 (12.05.2009) EP

(71) Applicants *(for all designated States except US)*: **ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC** [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (US). **ADDEX PHARMA S.A.** [CH/CH]; 12, Chemin des AuIx, CH-1228 Plan-les-Ouates (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CID-NÚÑEZ, José, Maria** [ES/ES]; Janssen-Cilag, S.A., CaIle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **DE LUCAS OLIVARES, Ana, Isabel** [ES/ES]; Janssen-Cilag, S.A., CaIle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **TRABANCO-SUÁREZ, Andres, Avelino** [ES/ES]; Janssen-Cilag, S.A., CaIle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **MACDONALD, Gregor, James** [GB/BE]; Janssen Pharmaceutics NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: **DEHNS**; St. Bride's House, 10 Salisbury Square, London EC4Y 8JD (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS



(I)

(57) Abstract: The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

WO 2010/130423 A1